INR Scientific Publications

Selected INR Scientific Publications

Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. Edward Tobinick MD. CNS Drugs. 2011 Feb 1; 25(2):145-155.
Perispinal etanercept: a new therapeutic paradigm in neurology. Edward Tobinick MD. Expert Review of Neurotherapeutics. 2010 Jun;10(6):985-1002.
Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. Edward Tobinick MD. CNS Drugs. 2009 Sep 1;23(9):713-25.
The value of drug repositioning in the current pharmaceutical market. Edward Tobinick MD. Drug News Perspect. 2009 Mar;22(2):119-25. Review.
Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. Edward Tobinick MD, K Chen PhD, X Chen PhD. BMC Res Notes. 2009 Feb 27;2:28.
Perispinal etanercept for neuroinflammatory disorders. Edward Tobinick MD. Drug Discovery Today. 2009 Feb;14(3-4):168-77.
Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Edward Tobinick MD. Medscape J Med. 2008 Jun 10;10(6):135.
Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. Edward Tobinick MD, H. Gross MD. BMC Neurology. 2008 Jul 21;8:27.
Re: Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Edward Tobinick MD. Neurology. 2008 Apr 1;70(14):1222-3.
Perispinal etanercept for treatment of Alzheimer’s disease. Edward Tobinick MD. Current Alzheimer Research. 2007 Dec;4(5):550-2.
A critique of intradiscal administration for treatment of radiculopathy. Edward Tobinick MD. Anesthesiology. 2008 Feb;108(2):334.
Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. Edward Tobinick MD, Hyman Gross MD. Journal of Neuroinflammation. 2008 Jan 9;5:2.
Spinal delivery of p38: TNF-alpha inhibitors. E Tobinick MD. PLoS Med. 2006 Nov;3(11):e511.
TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. Edward Tobinick MD, Hyman Gross MD, Alan Weinberger MD, Hart Cohen MD. MedGenMed. 2006 Apr 26;8(2):25.
The cerebrospinal venous system: anatomy, physiology, and clinical implications. Edward Tobinick MD. MedGenMed. 2006 Feb 22;8(1):53.
Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Edward Tobinick MD, Susan Davoodifar MD. Curr Med Res Opin. 2004 Jul;20(7):1075-85.
Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Edward L. Tobinick MD. Clinical Therapeutics. 2003 Aug;25(8):2279-88.
Perispinal TNF-alpha inhibition for discogenic pain. Edward L. Tobinick MD, Susan Britschgi-Davoodifar. Swiss Med Wkly. 2003 Mar; 133(11-12):170–7.

Please see the following publications by scientists independent of the INR for additional scientific background:

Therapeutic evaluation of etanercept in a model of traumatic brain injury.Chio CC, Lin JW, Chang MW, Wang CC, Kuo JR, Yang CZ, Chang CP. J Neurochem. 2010 Nov;115(4):921-9.
Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases. Frankola KA, Greig NH, Luo W, Tweedie D. CNS Neurol Disord Drug Targets. 2011 Feb 2.
Anti-TNF therapy in the injured spinal cord. Esposito E, Cuzzocrea S. Trends Pharmacol Sci. 2011 Feb;32(2):107-15. Epub 2010 Dec 23.
Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats. Shen CH, Tsai RY, Shih MS, Lin SL, Tai YH, Chien CC, Wong CS. Anesth Analg. 2011 Feb;112(2):454-9.
Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Shi JQ, Shen W, Chen J, Wang BR, Zhong LL, Zhu YW, Zhu HQ, Zhang QQ, Zhang YD, Xu J. Brain Res. 2011 Jan 12;1368:239-47.
Attenuation of Inflammatory Events in Human Intervertebral Disc Cells with a Tumor Necrosis Factor Antagonist. Sinclair SM, Shamji MF, Chen J, Jing L, Richardson WJ, Brown CR, Fitch RD, Setton LA. Spine (Phila Pa 1976). 2011 Jan 6.
Intrathecal inflammation precedes development of Alzheimer’s disease. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1200-5.
Perispinal etanercept: potential as an Alzheimer therapeutic.Griffin WS. J Neuroinflammation. 2008 Jan 10;5:3.
Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Park KM, Bowers WJ. Cell Signal. 2010 Jul;22(7):977-83.
The roles of TNF in brain dysfunction and disease. Clark IA, Alleva LM, Vissel B. Pharmacol Ther. 2010 Dec;128(3):519-48.
An association study of 21 potential Alzheimer’s disease risk genes in a Finnish population. Sarajärvi T, Helisalmi S, Antikainen L, Mäkinen P, Koivisto AM, Herukka SK, Haapasalo A, Soininen H, Hiltunen M. J Alzheimers Dis. 2010;21(3):763-7.
The role of TNF-alpha signaling pathway on COX-2 upregulation and cognitive decline induced by beta-amyloid peptide.Medeiros R, Figueiredo CP, Pandolfo P, Duarte FS, Prediger RD, Passos GF, Calixto JB. Behav Brain Res. 2010 May 1;209(1):165-73.
Soluble TNF receptors are associated with A-beta metabolism and conversion to dementia in subjects with mild cognitive impairment. Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O. Neurobiol Aging. 2010 Nov;31(11):1877-84.
Inflammation and anti-inflammatory strategies for Alzheimer’s disease–a mini-review. McNaull BB, Todd S, McGuinness B, Passmore AP. Gerontology. 2010;56(1):3-14.
Systemic inflammation and disease progression in Alzheimer disease. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH. Neurology. 2009 Sep 8;73(10):768-74.
Paths to acceptance. The advancement of scientific knowledge is an uphill struggle against ‘accepted wisdom’. Wolinsky H. EMBO Rep. 2008 May;9(5):416-8.

Request a Consultation

Call the INR at (310) 824-6199 or complete our online form to request a consultation with an INR Physician to discuss the patented INR Pain Breakthrough treatment.

Form Here

About the Institute

The INR® provides innovative care for patients with selected neurological disorders using pioneering methods of anti-TNF treatment developed through more than a decade of INR research. The INR treatment methods are breakthroughs in the field of neurological therapeutics. In addition to patient care, the INR has an active physician training program that has been attended by physicians from five continents. Patented INR anti-TNF treatment is available for patients with back pain, sciatica, neck pain, failed back surgery syndrome, other forms of chronic pain, and additional neurological disorders. More Info

World Leader in Anti-TNF Pain Treatment

(310) 824-6199

INR Scientific Publications

Request a Consultation

About the Institute

© Copyright 2001-2012 Institute of Neurological Recovery. All Rights Reserved